Cerivastatin sodium
Based on 2 publication(s) in Google Scholar
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 143201-11-0
- Formula: C26H33FNNaO5
- Molecular Weight:481.53
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Ferroptosis Compound Library
HY-L051
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Lipid Metabolism Compound Library
HY-L091
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Cerivastatin sodium
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.7 μM
Compound: Cerivastatin sodium
|
Antiproliferative activity against human A2780 cells incubated for 4 days by MTT assay
Antiproliferative activity against human A2780 cells incubated for 4 days by MTT assay
|
[PMID: 31803394] |
| Hepatocyte | IC50 |
1.7 nM
Compound: cer, cerivastatin
|
Inhibition of cholesterol synthesis in rat liver hepatocytes after 4 hrs
Inhibition of cholesterol synthesis in rat liver hepatocytes after 4 hrs
|
[PMID: 17560788] |
| HepG2 | IC50 |
0.13 μM
Compound: Cerivastatin
|
Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size after 72 hrs by fluorescent image analysis
Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size after 72 hrs by fluorescent image analysis
|
[PMID: 27105029] |
| HepG2 | IC50 |
0.34 μM
Compound: Cerivastatin
|
Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level after 72 hrs by fluorescent image analysis
Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level after 72 hrs by fluorescent image analysis
|
[PMID: 27105029] |
| HepG2 | IC50 |
0.6 μM
Compound: Cerivastatin
|
Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential after 72 hrs by fluorescent image analysis
Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential after 72 hrs by fluorescent image analysis
|
[PMID: 27105029] |
| HepG2 | IC50 |
0.8 μM
Compound: Cerivastatin
|
Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability after 72 hrs by fluorescent image analysis
Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability after 72 hrs by fluorescent image analysis
|
[PMID: 27105029] |
| HepG2 | IC50 |
0.96 μM
Compound: Cerivastatin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell number after 72 hrs by fluorescent image analysis
Cytotoxicity against human HepG2 cells assessed as reduction in cell number after 72 hrs by fluorescent image analysis
|
[PMID: 27105029] |
| L6 | IC50 |
7 nM
Compound: cer, cerivastatin
|
Inhibition of cholesterol synthesis in rat L6 cells after 3 hrs
Inhibition of cholesterol synthesis in rat L6 cells after 3 hrs
|
[PMID: 17560788] |
| NCI-H460 | IC50 |
3.5 μM
Compound: Cerivastatin sodium
|
Antiproliferative activity against human H460 cells incubated for 4 days by MTT assay
Antiproliferative activity against human H460 cells incubated for 4 days by MTT assay
|
[PMID: 31803394] |
Cerivastatin sodium (5-50 ng/mL; 3 days; MDA-MB-231 cells) treatment induces a dose-dependent decrease in cell proliferation of MDA-MB-231 cells (up to 40% inhibition at 25 ng/mL)[1].
Cerivastatin sodium (25 ng/mL; 18-36 hours; MDA-MB-231 cells) treatment induces an arrest of the cell cycle in G 1/S phase after 36 h treatment. This arrest is not observed for a shorter incubation time (18 h)[1].
Cerivastatin sodium (25 ng/mL; 18 hours; MDA-MB-231 cells) treatment induces a marked increase in the level of p21Waf1/Cip1[1].
Cerivastatin sodium (25 ng/mL; 12 hours; MDA-MB-231 cells) treatment increases the p21 transcript in MDA-MB-231 cells[1].
Cerivastatin sodium (10-25 ng/mL; 18 hours) inhibits invasion of MDA-MB-231 cells through Matrigel[1].
Cerivastatin sodium (25 ng/mL; 18-36 hours) delocalizes RhoA and Ras from the membrane to the cytosol and induces morphological changes[1].
Cerivastatin sodium (25 ng/mL; 4-36 hours) induces inactivation of NFκB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, and concomitantly increases IκB[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:5 ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL
-
Incubation Time:3 days
-
Result:Induced a dose-dependent decrease in cell proliferation of MDA-MB-231 cells.
-
Cell Line:MDA-MB-231 cells
-
Concentration:25 ng/mL
-
Incubation Time:18 hours, 36 hours
-
Result:Induced a cell cycle block in G 1/S phase.
-
Cell Line:MDA-MB-231 cells
-
Concentration:25 ng/mL
-
Incubation Time:18 hours
-
Result:Induced a marked increase in the level of p21Waf1/Cip1.
-
Cell Line:MDA-MB-231 cells
-
Concentration:25 ng/mL
-
Incubation Time:12 hours
-
Result:Increased p21Waf1/Cip1 mRNA levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 143201-11-0
-
Appearance Solid
-
Molecular Weight 481.53
-
Formula C26H33FNNaO5
-
Color White to off-white
-
SMILES
O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C(COC)=C(C(C)C)N=C1C(C)C.[Na+]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Integrated identification and mechanism exploration of bioactive ingredients from Salvia miltiorrhiza to induce vascular normalization. [Abstract]2025 Mar:138:156427. PMID: 39892310 -
Solvent & Solubility
H2O : 100 mg/mL (207.67 mM; ultrasonic and warming and heat to 60°C)
DMSO : 50 mg/mL (103.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Denoyelle C, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22(8):1139-48. [Content Brief]
[2]. Stein E, et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997 Jan;2(1):7-16. [Content Brief]
[3]. Furberg CD, et al. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-207. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.0767 mL | 10.3836 mL | 20.7671 mL | 51.9178 mL |
| 5 mM | 0.4153 mL | 2.0767 mL | 4.1534 mL | 10.3836 mL | |
| 10 mM | 0.2077 mL | 1.0384 mL | 2.0767 mL | 5.1918 mL | |
| 15 mM | 0.1384 mL | 0.6922 mL | 1.3845 mL | 3.4612 mL | |
| 20 mM | 0.1038 mL | 0.5192 mL | 1.0384 mL | 2.5959 mL | |
| 25 mM | 0.0831 mL | 0.4153 mL | 0.8307 mL | 2.0767 mL | |
| 30 mM | 0.0692 mL | 0.3461 mL | 0.6922 mL | 1.7306 mL | |
| 40 mM | 0.0519 mL | 0.2596 mL | 0.5192 mL | 1.2979 mL | |
| 50 mM | 0.0415 mL | 0.2077 mL | 0.4153 mL | 1.0384 mL | |
| 60 mM | 0.0346 mL | 0.1731 mL | 0.3461 mL | 0.8653 mL | |
| 80 mM | 0.0260 mL | 0.1298 mL | 0.2596 mL | 0.6490 mL | |
| 100 mM | 0.0208 mL | 0.1038 mL | 0.2077 mL | 0.5192 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cerivastatin sodium Related Classifications
HY-109523 Related Classifications
Powered by Bioz